多种质母细胞瘤中的分子机制和治疗点:网络和单细胞分析
Xiangyu Chen1, Xiao Zhong1, Feifei Zhang2
1Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Institute for Brain Science and Disease, Chongqing Medical University, Chongqing, 400016, China.
Scientific reports
|March 28, 2025
概括
这项研究揭示了质母细胞瘤瘤微环境 (TME) 中的关键基因和途径,这些基因和途径会影响患者的生存和治疗反应. 这些发现表明,针对个性化质母细胞瘤治疗策略的新型治疗点.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤,受到其复杂瘤微环境 (TME) 的显著影响.
- 了解TME的作用对于开发有效的GBM治疗和改善患者生存结果至关重要.
研究的目的:
- 调查TME对GBM进展和治疗耐药性的贡献.
- 确定新的预后生物标志物和GBM的治疗点.
主要方法:
- 从基因表达综合 (GEO) 来分析与质瘤相关的微阵列和单细胞RNA测序 (scRNA-seq) 数据集.
- 功能性丰富,加权基因同表达网络分析,以及使用LASSO进行Cox回归以开发预后特征.
- 差异基因表达分析专注于细胞外矩阵 (ECM) 改造和使用GDSC和CTRP数据库进行药物敏感性分析.
主要成果:
- 在高风险和低风险的GBM患者群体之间确定了不同的免疫特征,代谢变化和药物敏感性.
- 一个17基因的预后特征,包括COL1A1,COL4A1和VIM,与GBM患者的存活率显著相关.
- 参与细胞外基因 (ECM) 和突触重塑的关键基因被确定为GBM的关键驱动因素.
结论:
- 这项研究强调了ECM和突触重塑在GBM病变发生中的关键作用.
- 已识别的预后标志物和潜在的向疗法 (例如,SB-505,124,稳素,AZD8186) 提供了个性化GBM治疗策略的途径.
更多相关视频
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
相关概念视频
02:26Protein Networks
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...